Value Investing 10-[KQ] and XBRL analysis |
| Posted: 02 Jun 2019 03:54 AM PDT I started messing around with Natural Language Processing and analysing data from the Edgar database. It's kind of taken over my life as a side project, but wanted to get an idea of what fundamental ratios people work with, as well as things they like to pull out of 10Q and 10K filings to build it into the system. I'll be open sourcing the work, but wanted to get something up and useful before doing that. Thanks! [link] [comments]  |
| Posted: 01 Jun 2019 04:47 PM PDT '424B4' on 5/29/19 Brain model of the Reverse Acquisition -On May 8, 2019, they effected a one-for-ten reverse stock split -Unit= 1 share of Series C Convertible Preferred Stock and 125 warrants – Preferred Stock has a conversion price of $4.00 per share -Each Warrant will be exercisable for one share of our common stock – Broadridge Corporate Issuer Solutions, Inc. will serve as the Subscription and Information Agent for the Rights Offering. – We are also registering the shares of common stock issuable upon conversion of the Series C Preferred Stock and exercise of the Warrants. – We are authorized to issue up to 12,000,000 shares of capital stock, including 7,000,000 shares of common stock, and 5,000,000 shares of preferred stock – As of March 31, 2019, we had 2,610,970 shares of common stock , 278,530 shares of Series A Preferred Stock, 841,113 shares of Series B Preferred Stock, and one share of Special Voting Preferred Stock – 9,063 shares of common stock issuable upon exchange of Exchangeable Shares of 0959456 B.C. Ltd., a British Columbia corporation Ownership Structure – September 12, 2010, entered into a Patent Assignment Agreement with -Valent assigned to Del Mar (BC) its rights to patent applications – Valent loaned Del Mar $250,000 for the purchase of the prototype drug product under the Assignment on February 3, 2011 -Also assigned the prototype drug product related to VAL-083 – Del Mar paid $250 000 to acquire the prototype drug product – Valent is entitled to receive a future royalty on certain revenues derived from the development and commercialization of VAL-083 – The Assignment has a term of 10 years -Also subject to earlier termination in the event Del Mar breaches its payment obligations and fails to remedy such breach within 60 days – . The Valent loan(Valent loaned DMPI $250 000) is unsecured, bears interest at 3% per year, and is payable on demand -On September 30, 2014, DMPI agreed with Valent to exchange the loan for 278,530 shares of our Series A preferred stock. The Series A preferred stock has an annual 3% dividend. – One of our officers, Dr. Dennis Brown, is a principal of Valent and as result Valent is a related party to us. source article: https://interactiveswingtrading.com/2019/05/31/4028/ [link] [comments]  |
| You are subscribed to email updates from Value Investing. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States | |
No comments:
Post a Comment